Medpace Holdings, Inc. (NASDAQ:MEDP) Holdings Cut by Forte Capital LLC ADV

Forte Capital LLC ADV decreased its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 3.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,112 shares of the company’s stock after selling 125 shares during the quarter. Forte Capital LLC ADV’s holdings in Medpace were worth $1,034,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. R Squared Ltd acquired a new position in shares of Medpace during the 4th quarter worth $30,000. Stone House Investment Management LLC acquired a new position in shares of Medpace during the 3rd quarter worth $33,000. Ashton Thomas Securities LLC acquired a new position in shares of Medpace during the 3rd quarter worth $37,000. Capital Performance Advisors LLP acquired a new position in shares of Medpace during the 3rd quarter worth $46,000. Finally, True Wealth Design LLC increased its stake in shares of Medpace by 16,800.0% during the 3rd quarter. True Wealth Design LLC now owns 169 shares of the company’s stock worth $56,000 after purchasing an additional 168 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 0.3 %

NASDAQ:MEDP opened at $344.85 on Friday. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The firm’s fifty day simple moving average is $343.28 and its 200 day simple moving average is $347.47. The firm has a market capitalization of $10.51 billion, a PE ratio of 27.30, a PEG ratio of 3.77 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Robert W. Baird increased their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and a consensus price target of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.